View in EDS

Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors

Saved in:
Bibliographic Details
Title: Helicobacter pylori serology is associated with worse overall survival in patients with melanoma treated with immune checkpoint inhibitors
Authors: Tonneau, M., Nolin-Lapalme, A., Kazandjian, S., Auclin, E., Panasci, J., Benlaifaoui, M., Ponce, M., Al-Saleh, A., Belkaid, W., Naimi, S., Mihalcioiu, C., Watson, I., Bouin, M., Miller, W., Hudson, M., Wong, M.K., Pezo, R.C., Turcotte, S., Bélanger, K., Jamal, R., Oster, P., Velin, D., Richard, C., Messaoudene, M., Elkrief, A., Routy, B.
Source: Oncoimmunology
OncoImmunology, Vol 11, Iss 1 (2022)
Oncoimmunology, vol. 11, no. 1, pp. 2096535
Publisher Information: Informa UK Limited, 2022.
Publication Year: 2022
Subject Terms: 0301 basic medicine, immune checkpoint inhibitor therapy, Lung Neoplasms, Helicobacter pylori, microbiome, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Syndrome, Metastatic melanoma, RC581-607, Helicobacter Infections, 3. Good health, 03 medical and health sciences, Carcinoma, Non-Small-Cell Lung/drug therapy, Helicobacter Infections/drug therapy, Helicobacter Infections/microbiology, Helicobacter pylori/physiology, Humans, Immune Checkpoint Inhibitors/therapeutic use, Lung Neoplasms/drug therapy, Melanoma/drug therapy, helicobacter pylori, non-small cell lung cancer, onco-immunology, Carcinoma, Non-Small-Cell Lung, Immunologic diseases. Allergy, Immune Checkpoint Inhibitors, Melanoma, RC254-282, Original Research
Description: The microbiome is now regarded as one of the hallmarks of cancer and several strategies to modify the gut microbiota to improve immune checkpoint inhibitor (ICI) activity are being evaluated in clinical trials. Preliminary data regarding the upper gastro-intestinal microbiota indicated that Helicobacter pylori seropositivity was associated with a negative prognosis in patients amenable to ICI. In 97 patients with advanced melanoma treated with ICI, we assessed the impact of H. pylori on outcomes and microbiome composition. We performed H. pylori serology and profiled the fecal microbiome with metagenomics sequencing. Among the 97 patients, 22% were H. pylori positive (Pos). H. pylori Pos patients had a significantly shorter overall survival (p = .02) compared to H. pylori negative (Neg) patients. In addition, objective response rate and progression-free survival were decreased in H. pylori Pos patients. Metagenomics sequencing did not reveal any difference in diversity indexes between the H. pylori groups. At the taxa level, Eubacterium ventriosum, Mediterraneibacter (Ruminococcus) torques, and Dorea formicigenerans were increased in the H. pylori Pos group, while Alistipes finegoldii, Hungatella hathewayi and Blautia producta were over-represented in the H. pylori Neg group. In a second independent cohort of patients with NSCLC, diversity indexes were similar in both groups and Bacteroides xylanisolvens was increased in H. pylori Neg patients. Our results demonstrated that the negative impact of H. pylori on outcomes seem to be independent from the fecal microbiome composition. These findings warrant further validation and development of therapeutic strategies to eradicate H. pylori in immuno-oncology arena.
Document Type: Article
Other literature type
File Description: application/pdf
Language: English
ISSN: 2162-402X
DOI: 10.1080/2162402x.2022.2096535
Access URL: https://pubmed.ncbi.nlm.nih.gov/35832043
https://doaj.org/article/adb7b6925dfe48898a2dcd6d9e30f8ad
https://serval.unil.ch/notice/serval:BIB_D970B474B020
http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_D970B474B0209
https://serval.unil.ch/resource/serval:BIB_D970B474B020.P001/REF.pdf
Rights: CC BY NC
URL: http://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (http://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Accession Number: edsair.doi.dedup.....4b97dd345c6a550c54ebc0486ffd42af
Database: OpenAIRE
Description
Abstract:The microbiome is now regarded as one of the hallmarks of cancer and several strategies to modify the gut microbiota to improve immune checkpoint inhibitor (ICI) activity are being evaluated in clinical trials. Preliminary data regarding the upper gastro-intestinal microbiota indicated that Helicobacter pylori seropositivity was associated with a negative prognosis in patients amenable to ICI. In 97 patients with advanced melanoma treated with ICI, we assessed the impact of H. pylori on outcomes and microbiome composition. We performed H. pylori serology and profiled the fecal microbiome with metagenomics sequencing. Among the 97 patients, 22% were H. pylori positive (Pos). H. pylori Pos patients had a significantly shorter overall survival (p = .02) compared to H. pylori negative (Neg) patients. In addition, objective response rate and progression-free survival were decreased in H. pylori Pos patients. Metagenomics sequencing did not reveal any difference in diversity indexes between the H. pylori groups. At the taxa level, Eubacterium ventriosum, Mediterraneibacter (Ruminococcus) torques, and Dorea formicigenerans were increased in the H. pylori Pos group, while Alistipes finegoldii, Hungatella hathewayi and Blautia producta were over-represented in the H. pylori Neg group. In a second independent cohort of patients with NSCLC, diversity indexes were similar in both groups and Bacteroides xylanisolvens was increased in H. pylori Neg patients. Our results demonstrated that the negative impact of H. pylori on outcomes seem to be independent from the fecal microbiome composition. These findings warrant further validation and development of therapeutic strategies to eradicate H. pylori in immuno-oncology arena.
ISSN:2162402X
DOI:10.1080/2162402x.2022.2096535